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Editorial on the Research Topic
Understanding Crohn’s Disease: Immunity, Genes and Microbes
Crohn’s disease (CD) is a chronic debilitating syndrome, associated with considerable morbidity and 
resulting in elevated public health costs every year. CD and ulcerative colitis (UC) are the two major 
forms of inflammatory bowel disease (IBD), which has long been characterized as an exacerbated 
inflammatory response to common antigenic stimuli in the gut due to immune dysregulation. 
Although both CD and UC share some common patterns, they are distinct diseases. In fact, while UC 
is characterized by a diffuse mucosal inflammation involving mainly the rectum and adjacent colonic 
tissue, CD is a transmural inflammatory disease that may involve any part of the gastrointestinal 
tract, from the mouth to the anus, although in most cases the terminal ileum is affected. Etiology 
of IBD, particularly CD, has been long debated and is likely to involve the contribution of multiple 
factors, making its study challenging. Among those contributing factors are genetic inheritance, 
epigenetic mechanisms, infection with particular pathobionts, and the gut microbiota in general. 
This topic aimed at bringing together contributions covering aspects related primarily to CD etiol-
ogy and immunopathology, helping to drive forward a more comprehensive understanding of this 
challenging syndrome.
Genetic inheritance is an important predisposing factor for IBD. In a comprehensive review, 
Loddo and Romano point out the importance of genetic traits in susceptibility to IBD. The authors 
discuss the success of next-generation sequencing in the investigation of rare monogenic susceptibil-
ity variants, implicated in early-onset and very early-onset IBD. They also address the importance of 
epigenetic mechanisms, such as DNA methylation, in linking environmental stress and gene expres-
sion and discuss the use of microRNAs as biomarkers and therapeutical targets in IBD. The first 
genetic variant conferring susceptibility to ileal CD was located in the nucleotide oligomerization 
domain 2 (NOD2) gene (1), a gene implicated in recognition of bacterial muramyl dipeptide. Sidiq 
et al. highlight the role played by epithelial cell NOD2 expression in maintaining gut homeostasis 
and regulating ileal microbiota composition and address the consequences of a deficient NOD2 
variant in gut dysregulation. As described in an original research article, Parkhouse and Monie 
tested whether loss-of-function NOD2 variants conferring susceptibility to CD (R702W, G908R, 
and L1007fsincC) exhibited deficient binding to receptor-interacting protein kinase 2, an adaptor 
protein implicated in NOD2 signaling. They found that impairment of NOD2 signaling shown by 
variants containing CD-susceptibility polymorphisms did not correlate with deficient RIP2 binding, 
concluding that the causes for impairment are multifactorial.
A set of articles included in this topic specifically relate to patterns of immune system function 
in CD. Di Giovangiulio et al. contributed with a comprehensive review on the neuromodulation 
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of the gut immune system. Indeed, the cross talk between the 
nervous system and the gut immune system can shape the 
mucosal immune response to gut antigens and contribute to 
gut homeostasis. It is widely accepted that T cell function, par-
ticularly the interplay between regulatory and effector T  cells, 
is of major importance in the maintenance of gut tolerance to 
intestinal antigens. Sarrabayrouse et al. discuss the important 
role played by a unique human subset of Treg cells, the IL-10-
producers CD4CD8αα cells present in the intestinal mucosa. 
These cells are induced by clostridial bacteria to suppress T cell 
proliferation in a process independent on Foxp3 expression, since 
CD4CD8αα subset does not express this transcription factor. In a 
mini-review, Omenetti and Pizarro discuss the dynamic balance 
between intestinal Th17 and Treg cells, the plasticity allowing 
interdifferentiation and the participation of the gut microbiome 
in driving the differentiation toward each phenotype. Mucosal-
associated invariant T cells (MAIT cells) are a non-conventional 
T cell subset possibly playing a role in CD (2). MAIT cells make 
up 10% of peripheral blood and intestinal lamina propria T cells 
and express Th17  cells markers. In an opinion article, Treiner 
elegantly discusses arguments in favor of the participation 
of MAIT  cells in CD pathogenesis and presents two putative 
mechanisms by which activation of this T cell subset might occur 
in the gut.
In recent years, evidence is accumulating in favor of a central 
role of gut microbiota in CD pathogenesis. Three reviews included 
in this topic highlight the relevance of gut microbiota composition 
in health and disease. Haag and Siegmund discuss the interplay 
between intestinal microbiota and the innate immune system 
and the ways by which an altered microbiota may influence bar-
rier integrity and activate innate immunity, leading to chronic 
inflammation. Buttó et al. also address current approaches 
available to investigate microbiota-associated mechanisms of 
disease, such as new animal models. Oberc and Coombes discuss 
the impact of antibiotic treatment and infectious gastroenteritis 
(two external risk factors for CD) on gut microbiota composi-
tion, leading to dysbiosis and consequently to disease onset. Sechi 
and Dow mini-review addresses the long debated participation 
of Mycobacterium avium subsp. paratuberculosis (MAP) in CD 
etiology, discussing MAP exposure, human genetic susceptibility 
to mycobacterial infection and MAP possible involvement in CD, 
and other human inflammatory diseases.
Finally, in line with increasing recognition of the role played 
by nutrition in disease prophylaxis and therapy, Ferguson dis-
cusses the beneficial effects of directed nutritional therapy for CD 
patients, according to the genetic background and presence of 
particular susceptibility polymorphisms. Although data on the 
benefits of particular nutrients already exist, systems biology 
approaches would allow to validate efficacy of particular diet 
constituents to CD patients. This would help to drive nutritional 
therapy into the primary therapy in CD, integrated with currently 
accepted approaches.
I hereby wish to manifest my appreciation to all the authors 
that participated in this research topic. Their articles significantly 
contributed to a more comprehensive view on CD immuno-
pathology and associated factors, helping to improve current 
understanding of this debilitating disease.
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